History of hypersensitivity to durvalumab or tremelimumab or any excipients of these drugs.
History of hypersensitivity to tremelimumab, durvalumab, or any excipient
History of hypersensitivity to tremelimumab or any excipient
Has a history of hypersensitivity to durvalumab or tremelimumab excipient
History of hypersensitivity to durvalumab, tremelimumab or any excipient.
Willing to have peripheral blood mononuclear cells and bone marrow biopsies to be collected prior to receiving the first dose of durvalumab and tremelimumab, after -doses and -doses of durvalumab and tremelimumab, after nd treatment administration and th treatment administration.
History of hypersensitivity to the combination of durvalumab and tremelimumab.
History of hypersensitivity to durvalumab or tremelimumab or any excipient
Hypersensitivity to durvalumab or tremelimumab, or any excipients on the formulation
History of hypersensitivity to tremelimumab or any excipient
History of hypersensitivity to durvalumab, tremelimumab, SGI-, or any excipient
History of hypersensitivity to durvalumab, tremelimumab, or any excipient.
History of hypersensitivity to durvalumab (MEDI), tremelimumab, or any excipient
Receipt of the last dose of chemotherapy or tyrosine kinase inhibitors should be at least  weeks prior to durvalumab and tremelimumab dosing; monoclonal antibodies such as bevacizumab, ziv-aflibercept, ramucirumab, cetuximab, and panitumumab should be at least  weeks prior to durvalumab and tremelimumab therapy
History of hypersensitivity to durvalumab, tremelimumab, olaparib or, any excipient
History of hypersensitivity to tremelimumab or the combination of MEDI + tremelimumab
History of hypersensitivity to durvalumab or tremelimumab or any excipient
Treatment with other investigational agent within  weeks to the first dose of tremelimumab or durvalumab
History of hypersensitivity to durvalumab, tremelimumab or any excipient
Patients should agree to not donate blood while participating in this study or for at least  days following the last infusion of durvalumab or tremelimumab
History of hypersensitivity to tremelimumab
History of hypersensitivity to durvalumab, tremelimumab or any excipient
Patients should agree to not donate blood while participating in this study or for at least  days following the last infusion of durvalumab or tremelimumab